Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Recruiting 21Active not recruiting 17Not yet recruiting 5Terminated 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 4Lymphoid 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Hodgkin Disease 1Carcinoma, Ovarian Epithelial 1

Interventions

Specimen Handling 64Magnetic Resonance Spectroscopy 44Carboplatin 34Cyclophosphamide 31Gemcitabine 29Biopsy 28Cisplatin 27Radiotherapy 26pembrolizumab 25Bevacizumab 25Paclitaxel 23Standard of Care 22Oxaliplatin 22Drug Therapy 22venetoclax 21Nivolumab 21Capecitabine 21fludarabine 20Injections 20Interviews as Topic 18Radiosurgery 16Dexamethasone 16Blood Specimen Collection 16Azacitidine 16toripalimab 15tislelizumab 14cemiplimab 13anlotinib 13Irinotecan 13Pemetrexed 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × liposomal doxorubicin × 90 days × Clear all
NCT07021989 2026-06-04

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

University of California, San Francisco

Phase 2 Not yet recruiting
38 enrolled
Lymphoid

Hodgkin Disease

NCT07504588 2026-06-03

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
87 enrolled
Gynecologic

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT07604766 2026-06-02

RAINFOL-02

Genmab

Phase 3 Not yet recruiting
82 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07286266 2026-05-27

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

GlaxoSmithKline

Phase 3 Not yet recruiting
450 enrolled
Gynecologic

Ovarian Neoplasms

NCT07545460 2026-04-22

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
404 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡